Evolving Systemic Treatments for Hepatocellular Carcinoma: Multidisciplinary Strategies
Released On
March 31, 2023
Expires On
March 30, 2024
Media Type
Internet
Completion Time
50 minutes
Specialty
Hematology-Oncology
Topic(s)
Oncology
This activity is jointly provided by Association of Community Cancer Centers and The France Foundation.
This activity is supported by an educational grant from AstraZeneca.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — 1.0 Contact Hour
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity is intended for medical oncologists and other members of the health care team who care for patients with hepatocellular carcinoma (HCC).
Program Overview
This activity provides the latest clinical information to increase clinicians’ knowledge and improve their competence in providing the most accurate recommendations for treatment as members of the multidisciplinary hepatocellular carcinoma (HCC) cancer treatment team.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Apply strategies for early and accurate diagnosis of HCC stages
- Summarize mechanisms of action and clinical profiles of new and emerging immuno-oncology (IO) agents (mono and combo) for each stage of HCC
- Analyze data on IO therapy with liver-directed therapy procedures to identify appropriate patients
- Describe the role of HCC care team members and explain techniques to increase communication and collaboration
Faculty
Adam Burgoyne, MD, PhD
Chair of the Steering Committee
Associate Clinical Professor
Department of Medicine
Division of Hematology/Oncology
University of California, San Diego
San Diego, California
Stacey Stein, MD
Associate Professor of Internal Medicine
Assistant Medical Director, Clinical Trials Office
Yale Medicine
New Haven, Connecticut
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by The France Foundation and Association of Community Cancer Centers. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physicians:
The France Foundation designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Nurses:
The France Foundation designates this activity for 1.0 contact hour.
Disclosures of Conflicts of Interest
- Adam Burgoyne, MD, PhD
- Non-CE Consulting: Genentech, Exelixis, Deciphera, Kuur Therapeutics, CCO
- Non-CE Speakers Bureau: Deciphera, AstraZeneca
- Contract Research: Genentech, Exelixis, Hengrui, AstraZeneca, Deciphera, Merck
- Stacey Stein, MD
- Non-CE Consulting: AstraZeneca, Eisai, Exelixis Genentech, Imvax
Instructions for Participation and Credit
There are no fees for participating and receiving credit for this enduring activity. To receive credit participants must:
- Read the CE information and faculty disclosures.
- Complete the pre-test.
- Participate in the online activity.
- Complete post-test questions and submit the evaluation form.
Certificates will be emailed to the participant.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
TFF and ACCC require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ACCC do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Disclaimer
The France Foundation and Association of Community Cancer Centers present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and Association of Community Cancer Centers and the commercial supporter(s) assume no liability for the information herein.
Contact Information
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or [email protected].